Pharmacoeconomics in COPD: lessons for the future

References

• AnderssonFBorgSJanssonSAThe costs of exacerbations in chronic obstructive pulmonary disease (COPD)Respiratory Medicine200296700812243316
   PubMed Web of Science ®Google Scholar
• AnthonisenNSkeansMAWiseRAThe effects of a smoking cessation intervention on 14.5 year mortalityAnnals of Internal Medicine2005142233915710956
   PubMed Web of Science ®Google Scholar
• AyresJGPriceMJEfthimiouJCost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trialRespiratory Medicine2003972122012645827
   PubMed Web of Science ®Google Scholar
• BakerCBJohnsrudMTLynn CrismonJMQuantitative analysis of sponsorship bias in economic studies of antidepressantsBritish Journal of Psychiatry200318349850614645020
   PubMed Web of Science ®Google Scholar
• BaltussenRLeidlRAmentAReal world designs in economic evaluation: brigding the gap between clinical research and policy-makingPharmacoeconomics1999164495810662392
   PubMed Web of Science ®Google Scholar
• BellCMUrbachDRRayJGBias in published cost effectiveness studies: systematic reviewBMJ200633269970316495332
   PubMed Web of Science ®Google Scholar
• BriggsAHProbabilistic analysis of cost-effectiveness odels: choosing between treatment strategies for gastroesophageal reflux diseaseMedical Decision Making20022229030812150595
   PubMed Web of Science ®Google Scholar
• BriggsAHLozano-OrtegaGSpencerSEstimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing dataValue in Health200692273516903992
   PubMed Web of Science ®Google Scholar
• BriggsAHO’BrienBJThe death of cost-minimisation analysis?Health Economics2001101798411252048
   PubMed Web of Science ®Google Scholar
• BrittonMThe burden of COPD in the U.K.: results from the Confronting COPD surveyRespiratory Medicine200397Suppl CS71912647945
   PubMed Web of Science ®Google Scholar
• CalverleyPMBellamyDThe challenge of providing better care for patients with chronic obstructive pulmonary disease: the poor relation of airways obstruction?Thorax200055788210607806
   PubMed Web of Science ®Google Scholar
• CalverleyPMSondhiSThe burden of obstructive lung disease in the UK - COPD and asthmaThorax199853Supp 4A83
   Google Scholar
• ChapmanKRBourbeauJRanceLThe burden of COPD in Canada: results from the Confronting COPD surveyRespiratory Medicine200397Suppl CS233112647940
   PubMed Web of Science ®Google Scholar
• ClaxtonKSculpherMDrummondMA rational framework for decision making by the National Institute for Clinical Excellence (NICE)The Lancet200236071115
   PubMed Web of Science ®Google Scholar
• ClaxtonKSculpherMMcCabeCProbabilistic sensitivity analysis for NICE technology assessment: not an optional extraHealth Economics2005143394715736142
   PubMed Web of Science ®Google Scholar
• CookJDrummondMHeyesJEconomic endpoints in clinical trialsStatistical Methods in Medical Research2004131577615068259
   PubMed Web of Science ®Google Scholar
• CulyerAMcCabeCBriggsASearching for a threshold, not setting one: the role of the National Institute for Health and Clinical ExcellenceJournal of Health Services Research and Policy20071256817244400
   PubMedGoogle Scholar
• DahlRGreefhorstLANowakDInhaled formoterol dry powder versus ipratroipumbromide in chronic obstructive pulmonary diseaseAmerican Journal of Respiratory and Critical Care Medicine20011647788411549532
   PubMed Web of Science ®Google Scholar
• Dal NegroRRossiACerveriIThe burden of COPD in Italy: results from the confronting COPD surveyRespiratory Medicine200397Suppl CS435012647942
   PubMed Web of Science ®Google Scholar
• DrummondMFSculpherMJTorranceGWMethods for the economic evaluation of health care programmes20053Oxford University Press
   Google Scholar
• DrummondMSculpherMCommon methodological flaws in economic evaluationsMedical Care2005437 SupplII514
   Web of Science ®Google Scholar
• European Respiratory Society and European Lung FoundationChronic obstructive pulmonary diseaseEuropean lung white book2003HuddersfieldERSJ
   Google Scholar
• FletcherCPetoRThe natural history of chronic airflow obstructionBritish Medical Journal1977116458871704
   PubMed Web of Science ®Google Scholar
• FriedmanMSC.M.Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPDChest19991156354110084468
   PubMed Web of Science ®Google Scholar
• FukuchiYNishimuraMIchinoseMCOPD in Japan: The Nippon COPD Epidemiology studyRespirology20049414982595
   PubMed Web of Science ®Google Scholar
• GagnonYMLevyARSpencerMDEconomic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organizationRespiratory Medicine20059915344516291076
   PubMed Web of Science ®Google Scholar
• GarberAMCulyerANewhouseJAdvances in cost-effectiveness analysis of health interventionsHandbook of health economics20001AmsterdamElsevier BV181221
   Google Scholar
• GOLDGlobal initiative for chronic obstructive lung disease2006
   Google Scholar
• GoldMSiegelJERusselLBCost-effectiveness in health and medicine1996New YorkOxford Universty Press
   Google Scholar
• GrossNOutcome measures for COPD treatments: a critical evaluationCOPD: Journal of Chronic Obstructive Pulmonary Disease200414157
   Google Scholar
• GuestJFThe annual cost of chronic obstructive pulmonary disease to the UK’s National Health ServiceDisease Management and Health Outcomes199952
   Google Scholar
• HalpernMTStanfordRHBorkerRThe burden of COPD in the U.S.A.: results from the Confronting COPD surveyRespiratory Medicine200397Suppl CS81912647946
   PubMed Web of Science ®Google Scholar
• HalpinDMHealth economics of chronic obstructive pulmonary disease. [Review] [70 refs]Proceedings of the American Thoracic Society200632273316636090
   PubMedGoogle Scholar
• HoganTJGeddesRGonzalezEAn economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary diseaseClinical Therapeutics2003252859712637127
   PubMed Web of Science ®Google Scholar
• ISPORPharmacoeconomic guidelines around the world [online]2007 URL: http://www.ispor.org/PEguidelines/index.asp
   Google Scholar
• IzquierdoJLThe burden of COPD in Spain: results from the Confronting COPD surveyRespiratory Medicine200397Suppl CS61912647944
   PubMed Web of Science ®Google Scholar
• JanssonSAAnderssonFBorgSCosts of COPD in Sweden according to disease severityChest20021221994200212475838
   PubMed Web of Science ®Google Scholar
• JemalAWardEHaoYTrends in the leading causes of death in the United States, 1970–2002JAMA200529414
   Web of Science ®Google Scholar
• JonesPWWilsonKSCost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluationRespiratory Medicine20039720612556006
   PubMed Web of Science ®Google Scholar
• JubranAGrossNRamsdellJComparative cost-effectiveness analysis of theophylline and ipratropium bromide in chronic obstructive pulmonary disease. A three-centre studyChest1993103678848449051
   PubMed Web of Science ®Google Scholar
• LofdahlCGEricssonASvenssonKCost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alonePharmacoeconomics2005233657515853436
   PubMed Web of Science ®Google Scholar
• LokkeALangePScharlingHDeveloping COPD: a 25 year follow up study of the general populationThorax200661935917071833
   PubMed Web of Science ®Google Scholar
• Lung and Asthma Information AgencyTrends in COPD [pamphlet]2003
   Google Scholar
• MackayJEriksenMThe tobacco atlas2002World Health Organization
   Google Scholar
• ManiadakisNTzanakisNFragoulakisVEconomic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in GreeceCurrent Medical Research and Opinion2006228
   Web of Science ®Google Scholar
• McGuireAIrwinDEFennPThe excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and WalesValue in Health20014511704971
   PubMedGoogle Scholar
• Murray ChristopherJLLopezADMathersCDThe Global Burden of Disease 2000 project: aims, methods and data sources2001World Health Organization
   Google Scholar
• National Institute for Clinical ExcellenceGuide to the methods of technology appraisal2004LondonNational Institute for Clinical Excellence
   Google Scholar
• National Institute of Health and Clinical ExcellenceA guide to NICE [pamphlet]2005
   Google Scholar
• OostenbrinkJBRutten-van MolkenMPMonzBUProbabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries [see comment]Value in Health20058324615841892
   PubMed Web of Science ®Google Scholar
• OostenbrinkJBRutten-van MolkenMPOne-year cost-effectiveness of tiotropium versus ipratopium to treat chronic obstructive pulmonary diseaseEuropean Respiratory Journal2004232
   Web of Science ®Google Scholar
• PhilipsZBojkeLSculpherMGood practice guidelines for decision-analytic modelling in Health Technology Assessment: A review and consolidation of quality assessmentPharmacoeconomics2006243557116605282
   PubMed Web of Science ®Google Scholar
• PipernoDHuchonGPribilCThe burden of COPD in France: results from the Confronting COPD surveyRespiratory Medicine200397Suppl CS334212647941
   PubMed Web of Science ®Google Scholar
• RuchlinHSDasbachEJAn economic overview of chronic obstructive pulmonary diseasePharmacoeconomics2001196
   Web of Science ®Google Scholar
• Rutten-van MolkenMLeeTAAuthorsFNEconomic modeling in chronic obstructive pulmonary disease. [Review] [15 refs]Proceedings of the American Thoracic Society20063630416963546
   PubMedGoogle Scholar
• Rutten-van MolkenMVan DoorslaerEKJansenMCCosts and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary diseaseAmerican Journal of Respiratory and Critical Care Medicine1995151975827697275
   PubMed Web of Science ®Google Scholar
• SculpherMClaxtonKDrummondMWhither trial-based economic evaluation for health care decision making?Health Economics2006156778716491461
   PubMed Web of Science ®Google Scholar
• SculpherMJDrummondMFMcGuireAThe role and estimation of productivity costs in economic evaluationTheory and practice of economic evaluation in health2001OxfordOxford University Press
   Google Scholar
• SinDDGolmohammadiKJacobsPCost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severityAmerican Journal of Medicine20041163253114984818
   PubMed Web of Science ®Google Scholar
• SpencerMBriggsAHGrossmanRFDevelopment of an economic model to assess the cost-effectiveness of treatment interventions for chronic obstructive pulmonary diseasePharmacoeconomics2005236193715960557
   PubMed Web of Science ®Google Scholar
• SullivanSDThe burden of illness and economic evaluation for COPDEuropean Respiratory Journal200322Suppl 437S8S
   Google Scholar
• SullivanSDRamseySDLeeTAThe economic burden of COPDChest20001172 Suppl S5910631188
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human ServicesSummary health statistics for us adults: National Health Interview Survey, 20042004
   Google Scholar
• van den BoomGRThe cost effectiveness of early treatment with fluticasone propionate 250 microg twice a day in subjects with obstructive airway disease. Results of the DIMCA programAmerican Journal of Respiratory and Critical Care Medicine200116420576611739135
   PubMed Web of Science ®Google Scholar
• WoutersEFThe burden of COPD in The Netherlands: results from the Confronting COPD surveyRespiratory Medicine200397Suppl CS51912647943
   PubMed Web of Science ®Google Scholar
• YelinEKatzPBalmesJWork life of persons with asthma, rhinits, and COPD: A study using a national, population based sampleJournal of Occupational Medicine and Toxicology200612
   Google Scholar
• ZielinskiJBednarekMGoreckaDIncreasing COPD awarenessEuropean Respiratory Journal2006278335216585092
   PubMed Web of Science ®Google Scholar